Table 2 Pre to post-treatment means on key outcome measures

Goldstein et al. 2007

INT

K-SADS DRS: 23.1 (12.0)*

K-SADS-DRS: 14.9 (10.6)*

K-SADS MRS: 13.3 (12.1)

K-SADS MRS: 12.2 (14.2)

MSSI: 6.7*

MSSI: 0*

CALS-C: 36.1 (19.47)*

CALS-P: 35.5 (17.37)*

CALS-C: 17.78 (24.24)*

CALS-P: 27.88 (23.2)*

MESSY: N.R

MESSY: N.R

Goldstein et al. 2015

INT

K-SADS DRS: 25.71 (7.1)*

K-SADS DRS: 9.44 (9.14)*/**

K-SADS MRS: 27.14 (8.5)*

K-SADS MRS: 11.67 (7.89)*

SIQ-JR: 19.17 (21.0)

SIQ-JR: 4.29 (7.67)

CALS-C: 40.17 (19.1)*

CALS-P: 41.79 (15.8)*

CALS-C: 15.71 (11.32)*

CALS-P: 17.86 (12.95)*

–

–

CTL

K-SADS DRS: 19.17 (9.6)

K-SADS DRS: 16.5 (7.78)**

K-SADS MRS: 14.50 (6.7)

K-SADS MRS: 11.67 (7.89)

SIQ-JR: 15.50 (29.7)

SIQ-JR: 8 (9.9)

CALS-C: 31.00 (18)

CALS-P: 21 (14.3)

CALS-C:37.5 (34.65)

CALS-P: 30 (N.R.)

–

–

Van Dijk et al. 2013

Main study

INT

BDI-II: 24.6 (8.4)*

BDI-II: 7.9 (6.1)*

–

–

–

–

ACS Total: 4.4 (0.6)

ACS Total: 3.5 (0.6)

–

–

CTL

BDI-II: 33.7 (11.5)*

BDI-II: 23.58 (17.1)*

–

–

–

–

ACS Total: 4.6 (0.8)

ACS Total: 4.1 (1.5)

–

–

Secondary analysis

INT

BDI-II: 25.2 (11.9)*

BDI-II: 16.6 (14.0)*

–

–

–

–

ACS Total: 4.5 (0.9)*

ACS Total: 4.0 (1.2)*

–

–

Afshari et al. 2020

INT

BDI-II: 9.65 (5.82)

BDI-II: 6.42 (3.41)**

YMRS:15.65 (7.19)

YMRS: 10.88 (3.50)**

–

–

DERS:129.80

DERS: 120.07 (17.30)**

–

–

CTL

BDI-II:10.46 (5.97)

BDI-II: 10.14 (5.81)**

YMRS: 14.39 (7.47)

YMRS: 13.57 (6.96)**

–

–

DERS:136.5 (25.74)

DERS: 135.10 (25.14)**

–

–

Zargar et al. 2019

INT

BDI-II: 20.63 (16.03)

BDI-II: 26.00 (11.63)

YMRS: 4.79 (3.17)*

YMRS: 2.12 (3.09)*/**

–

–

ACS-EC: 172.27 (40.02)

ACS-A: 34.12 (10.40)

ACS-DM: 36.17(10.12)*

ACS-A: 51.78 (14.47)

ACS-PA: 49.68 (11.78)

ACS-EC: 162.27 (48.49)

ACS-A: 33.00 (11.11)

ACS-DM: 31.09 (8.98)*/**

ACS-A: 51.30 (16.23)

ACS-PA: 47.05 (15.78)

–

–

CTL

BDI-II: 28.28 (10.76)

BDI-II: 23.76 (11.78)

YMRS: 5.88 (2.91)

YMRS: 4.24 (4.11)**

–

–

ACS-EC: 180.61 (25.44)

ACS-Ang: 34.80 (10.39)

ACS-DM: 36.12 (8.31)

ACS-Anx: 54.67 (11.62)

ACS-PA: 54.76 (12.65)

ACS-EC: 188.91 (37.42)

ACS-Ang: 37.12 (10.10)

ACS-DM: 39.92 (9.05)**

ACS-Anx: 56.96 (13.31)

ACS-PA: 55.56 (11.88)

–

–

Wright et al. 2020

INT

BDI-II (ITT): 30.30 (11.23)*

PHQ-9 (ITT): 17.50 (6.67)*

BDI-II (ITT): 15.60 (10.81)*

PHQ-9: 10.00 ( 7.09)*

BMRS (ITT): 2.40 (2.59)

ASRM (ITT): 4.40 (4.55)

BMRS (ITT): 1.70 (2.54)

ASRM (ITT): 5.30 (2.11)

–

–

–

–

QoL-BD (ITT): 30.00 (6.61)*

IIP (PP): 58.44 (18.37)

QoL-BD (ITT): 38.67 (7.86)*

IIP (PP): 49.75 (18.27)

Wright et al. 2021

INT

HDRS: 12.8 (8.1)

PHQ-9:

15.5 (6.6)

HDRS: 8.5 (4.8)

PHQ-9: 10.3 (6.5)

BMRS: 1.8 (2.4)

BMRS: 1.8 (3.2)

–

–

ALS-Total: 37.3 (6.1)

ALS-Total: 26.0(13.5)

QoL-BD: 33.2 (7.5)

QoL-BD: 35.1 (8.3)

CTL

HDRS: 6.6 (4.2)

PHQ-9: 12.9 (5.2)

HDRS: 9.5 (5.8)

PHQ-9: 9.8 (4.9)

BMRS: 1.7 (1.8)

BMRS: 1.9 (2.5)

–

–

ALS-Total: 31.5 (13.1)

ALS-Total: 23.5 (12.2)

QoL-BD: 36.6 (6.8)

QoL-BD: 34.0 (10.7)

Valls et al. 2021

INT

HDRS: 6.7 (4.1)

HDRS: 5.0 (3.3)**

YMRS:2.32 (2.0)

YMRS: 2.0 (2.3)

–

–

–

–

FAST-Total: 23.18 (10.76)

FAST-C: 4.3 (3.3)

FAST-L: 2.4 (1.4)

4/6 FAST domains N.R

Qol.BD: 158.36 (29.5)

FAST-Total: 17.1 (9.3)**

FAST-C: 2.5 (2.3)**

FAST-L: 1.7 (1.28)**

4/6 FAST domains N.R

Qol.BD: 154.2 (27.9)

CTL

HDRS: 3.8 (3.3)

HDRS: 4.5 (4.3)**

YMRS: 1.05 (1.6)

YMRS: 1.22 (2.0)

–

–

–

–

FAST-Total: 22.95 (14.03)

FAST-C: N.R

FAST-L: N.R

4/6 FAST domains N.R

Qol-BD: 160.7 (38.1)

FAST-Total: 23.4 (14.7)**

FAST-C: N.R.**

FAST-L: N.R.**

4/6 FAST domains N.R

Qol-BD: 162.6 (31.59)

Eisner et al. 2017

INT

HDRS: 12.7 (6.0)

HDRS: 11.5 (5.7)

YMRS: 6.1 (6.2)

YMRS: 5.7 (4.0)

–

–

DERS: 107.6 (24.0)*

ERS: 52.2 (22.0)*

DERS: 92.8 (23.2)*

ERS: 44.1 (21.4)*

–

–

Painter et al. 2019

INT

mHDRS: 3.00 (2.86)

mHDRS: 3.82 (3.87)

YMRS: 2.83 (3.04)

YMRS: 4.6 (5.65)

–

–

ERQ-SE Reappraisal:23.83 (7.92)*

ERQ-SE Suppression: 14.67 (4.31)

ERQ-SE Reappraisal: 28.75 (8.13)*

ERQ-SE Suppression: 13.50 (6.59)

–

–